Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rac3-mediated transformation requires multiple effector pathways.

Patricia J Keller1, Christyn M Gable, Michele R Wing

  • 1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7512, USA.

Cancer Research
|November 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

Cell reports·2026
Same author

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.

bioRxiv : the preprint server for biology·2026
Same author

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance.

bioRxiv : the preprint server for biology·2026
Same author

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.

Cancer research·2025
Same author

Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer.

Science signaling·2025
Same author

KRAS: the Achilles' heel of pancreas cancer biology.

The Journal of clinical investigation·2025
Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026
Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
See all related articles

Rac3 small GTPase promotes cell transformation through multiple effector pathways, unlike Rac1. Specific mutants highlight distinct roles in anchorage independence and signaling, revealing complex cancer progression mechanisms.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Signal Transduction

Background:

  • Rac3, a Rac1 relative, promotes cell transformation, membrane ruffling, and c-jun activation.
  • Rac1 is implicated in cancer progression, prompting investigation into Rac3's role.
  • Understanding Rac signaling pathways is crucial for cancer research.

Purpose of the Study:

  • To investigate the relationship between Rac signaling, transformation, and effector usage using effector domain mutants (EDMs).
  • To identify specific pathways mediating Rac3-induced transformation and anchorage independence.
  • To compare Rac3 effector usage with that of Rac1.

Main Methods:

  • Utilized Rac3 effector domain mutants (EDMs) to assess membrane ruffling, focus formation, and anchorage independence.

Related Experiment Videos

  • Employed luciferase reporter assays and glutathione S-transferase (GST) pull-down assays to analyze signaling pathways and effector binding.
  • Investigated transcriptional activation of c-jun, serum response factor (SRF), and cyclin D1.

    • Main Results:

    • All tested Rac3 EDMs promoted membrane ruffling and focus formation, but only N43D induced anchorage independence.
    • Rac3 activation of phospholipase Cbeta2 links to serum response factor (SRF) signaling.
    • Rac3 binds poorly to Rac1 effectors MLK2 and MLK3; cyclin D1 transcription correlates with soft agar growth.

    Conclusions:

    • Rac3-mediated transformation requires multiple effector pathways, partially distinct from Rac1.
    • Activation of membrane ruffling and transcription factors like c-jun, SRF, or E2F alone is insufficient for Rac3-induced anchorage-independent growth.
    • Specific Rac3 effector interactions, particularly with phospholipase Cbeta2 and cyclin D1, are critical for its transforming activity.